Skip to main content

Table 1 Elesclomol-related clinical trials

From: Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy

Clinical Trial Subjects Staging of Clinical Trials Recruitment Status Drug use Results References
Acute myeloid leukemia Phase I Unknown Elesclomol sodium Elesclomol has a good clinical safety profile, but patients have not developed clinical responses to elesclomol 26732437
Solid tumors Phase I Completed Elesclomol sodium, Paclitaxel The combination of Elesclomol and paclitaxel was well tolerated by patients and the toxicity profile of elesclomol was similar to that of single agent paclitaxel 17255281
Melanoma Phase I/II Completed Elesclomol sodium, Paclitaxel The combination of elesclomol and paclitaxel resulted in a statistically significant doubling of median PFS, with an acceptable toxicity profile and encouraging OS 19826135
Melanoma Phase III Terminated Elesclomol sodium, Paclitaxel The combination of elesclomol and paclitaxel did not significantly improve PFS 23401447
Recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cancer Phase II Completed Elesclomol sodium, Paclitaxel The combination of elesclomol and paclitaxel was well tolerated by patients but the proportion responding was low 30309721
Solid tumors Phase I Suspended Elesclomol sodium Unpublished -
Prostate cancer Phase I Completed Elesclomol sodium, Docetaxel Unpublished -
Stage IIIB/IV non-small cell lung cancer Phase I/II Completed Elesclomol sodiuml, Paclitaxel, Carboplatin Unpublished -
Soft tissue sarcoma Phase II Completed Elesclomol sodium, taxane Elesclomol enhanced taxane efficacy by induction of Hsp70 16784029
  1. Elesclomol-related clinical trials were searched using the ClinicalTrials.gov platform. Nearly a dozen clinical trials related to elesclomol treatment have been conducted with the estimated enrollment of a thousand patients with different types of cancers, including melanoma, ovarian cancer, and acute myeloid leukemia. Unfortunately, according to published results, the clinical anticancer efficacy of elesclomol is suboptimal, but patients have good tolerance to elesclomol
  2. PFS Progression-free survival, OS Overall survival